Lupus anticoagulants may exhibit different levels in patients with malignancies, and high frequency of LAC was confirmed in patients with lung cancer.3,16 Some studies have shown that disorder of coagulating function may cause an initial hypercoagulable state with subclinical abnormalities and lead to abnormal levels of some hemostatic markers such as D-D, Fbg, FVIII, and AT in patients with cancer.20, , –23 In the present study, we found significantly increased levels of D-D, Fbg, and FVIII: C, and decreased AT activity in patients with NSCLC. This evidence concerns the gene F8 and lung cancer.